116 related articles for article (PubMed ID: 32513535)
21. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children.
Caramia G; Clemente E; Solli R; Mei V; Cera R; Carnelli V; Venturoli V; Corsini A
Arzneimittelforschung; 1994 Dec; 44(12A):1480-4. PubMed ID: 7857347
[TBL] [Abstract][Full Text] [Related]
22. Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.
Liu S; Han Z; Trivett AL; Lin H; Hannifin S; Yang D; Oppenheim JJ
Cancer Immunol Immunother; 2019 Jul; 68(7):1059-1071. PubMed ID: 30972427
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of pidotimod against experimental bacterial infections in mice.
Coppi G; Falcone A; Manzardo S
Arzneimittelforschung; 1994 Dec; 44(12A):1417-21. PubMed ID: 7857334
[TBL] [Abstract][Full Text] [Related]
24. Pidotimod: the past and the present.
Zuccotti GV; Mameli C
Ital J Pediatr; 2013 Dec; 39():75. PubMed ID: 24314100
[TBL] [Abstract][Full Text] [Related]
25. In vivo antiviral effects of pidotimod.
Dianzani C; Colangelo D; Tonso E; Guidotto S; Viano I
Arzneimittelforschung; 1994 Dec; 44(12A):1431-3. PubMed ID: 7857337
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness of pidotimod in combination with bacterial lysates in the treatment of the pfapa (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) syndrome].
Buongiorno A; Pierossi N
Minerva Pediatr; 2015 Jun; 67(3):219-26. PubMed ID: 25941128
[TBL] [Abstract][Full Text] [Related]
27. The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod(PTD).
Hu X; Zhang W; Wang L; Wan N; Wang B; Li W; Hua H; Hu X; Shan F
Hum Vaccin Immunother; 2012 Sep; 8(9):1250-8. PubMed ID: 22863756
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: a multicentre study.
Namazova-Baranova LS; Alekseeva AA; Kharit SM; Kozhevnikova TN; Taranushenko TE; Tuzankina IA; Scarci F
Int J Immunopathol Pharmacol; 2014; 27(3):413-9. PubMed ID: 25280032
[TBL] [Abstract][Full Text] [Related]
29. Preventive effect of pidotimod on reactivated toxoplasmosis in mice.
Huo XX; Wang L; Chen ZW; Chen H; Xu XC; Zhang AM; Song XR; Luo QL; Xu YH; Fu Y; Wang H; Du J; Cai YH; Lun ZR; Lu FL; Wang Y; Shen JL
Parasitol Res; 2013 Aug; 112(8):3041-51. PubMed ID: 23774843
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo evaluation of Pidotimod effect on immune response.
Pugliese A; Marinelli L; Forno B; Pollono AM; Uslenghi C; Girardello R
Pharmacol Res; 1992 Sep; 26 Suppl 2():178-9. PubMed ID: 1409298
[No Abstract] [Full Text] [Related]
31. Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod.
di Marco R; Condorelli F; Girardello R; Uslenghi C; Chisari G; di Mauro M; Speciale AM; Meroni PL; Nicoletti F
Scand J Infect Dis; 1992; 24(6):821-3. PubMed ID: 1287821
[TBL] [Abstract][Full Text] [Related]
32. [Astragalus polysaccharides combined with cisplatin decreases the serum levels of CD44 and collagen type IV and hyaluronic acid in mice bearing Lewis lung cancer].
Ming H; Chen Y; Zhang F; Wang Q; Dong X; Gu J; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jul; 31(7):909-13. PubMed ID: 26146060
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity of Lewis lung carcinoma to cisplatin undergoes considerable variations during growth and metastasizing.
Solyanik GI; Garmanchuk LV; Pyaskovskaya ON; Yakshibaeva YR; Gorbik GV
Bull Exp Biol Med; 2004 Sep; 138(3):295-7. PubMed ID: 15665927
[TBL] [Abstract][Full Text] [Related]
34. The in vitro effect of Pidotimod on some immune functions in cancer patients.
Di Renzo M; Pasqui AL; Bruni F; Saletti M; Bova G; Chiarion C; Girardello R; Ferrì P; Auteri A
Immunopharmacol Immunotoxicol; 1997 Feb; 19(1):37-51. PubMed ID: 9049658
[TBL] [Abstract][Full Text] [Related]
35. Effect of Pidotimod, a new immunostimulating agent, on some aspects of immune response. In vitro study.
Auteri A; Pasqui AL; Bruni F; Saletti M; Di Renzo M; Bova G
Pharmacol Res; 1992 Sep; 26 Suppl 2():196-7. PubMed ID: 1409308
[No Abstract] [Full Text] [Related]
36. Pidotimod in the management of recurrent pharyngotonsillar infections in childhood.
Passali D; Calearo C; Conticello S
Arzneimittelforschung; 1994 Dec; 44(12A):1511-6. PubMed ID: 7857354
[TBL] [Abstract][Full Text] [Related]
37. The concurrent treatment of Scutellaria baicalensis Georgi enhances the therapeutic efficacy of cisplatin but also attenuates chemotherapy-induced cachexia and acute kidney injury.
Huang TH; Wu TH; Guo YH; Li TL; Chan YL; Wu CJ
J Ethnopharmacol; 2019 Oct; 243():112075. PubMed ID: 31291609
[TBL] [Abstract][Full Text] [Related]
38. Effects of pidotimod soluble powder and immune enhancement of Newcastle disease vaccine in chickens.
Qu S; Dai C; Qiu M; Zhang R; Wang C; Cui L; Hao Z
Immunol Lett; 2017 Jul; 187():14-18. PubMed ID: 28487096
[TBL] [Abstract][Full Text] [Related]
39. Experimental immunological screening tests on pidotimod.
Coppi G; Manzardo S
Arzneimittelforschung; 1994 Dec; 44(12A):1411-6. PubMed ID: 7857333
[TBL] [Abstract][Full Text] [Related]
40. Modulating effects of the synthetic thymic dipeptide pidotimod on the immune system in the aging rat.
Chiarenza A; Iurato MP; Barbera N; Lempereur L; Cantarella G; Scapagnini U; Bernardini R
Pharmacol Toxicol; 1994; 74(4-5):262-6. PubMed ID: 8090697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
